Silo Pharma, Inc. - Common Stock (SILO)
0.5199
-0.3161 (-37.81%)
NASDAQ · Last Trade: May 15th, 6:40 PM EDT
Detailed Quote
| Previous Close | 0.8360 |
|---|---|
| Open | 0.5401 |
| Bid | 0.5100 |
| Ask | 0.5101 |
| Day's Range | 0.4800 - 0.5600 |
| 52 Week Range | 0.7100 - 4.500 |
| Volume | 2,313,371 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 416,161 |
Chart
About Silo Pharma, Inc. - Common Stock (SILO)
Silo Pharma Inc is a biotechnology company focused on leveraging psychedelic compounds and their therapeutic potential to treat various mental health conditions and neurological disorders. By researching and developing innovative drug delivery methods and formulations, the company aims to create effective treatments that can address unmet medical needs in the psychiatric space. Silo Pharma emphasizes collaboration with academic institutions and industry partners to advance its clinical programs and contribute to the evolving landscape of mental health therapies. Read More
News & Press Releases
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · May 15, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · May 15, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · May 15, 2025
InvestorkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical trial.
Via Investor Brand Network · May 15, 2025
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire five years thereafter. The Series A-2 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire eighteen months thereafter. The closing of the offering is expected to occur on or about May 16, 2025, subject to the satisfaction of customary closing conditions.
By Silo Pharma, Inc. · Via GlobeNewswire · May 15, 2025
The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.
Via Stocktwits · May 14, 2025
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
By Silo Pharma, Inc. · Via GlobeNewswire · May 14, 2025
Via Benzinga · May 14, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
Silo Pharma (NASDAQ: SILO) has partnered with Frontage Laboratories to conduct a 7-day safety and toxicology study of its lead asset, SPC-15, following a request from the FDA. The intranasal treatment targets PTSD and stress-related disorders, and the study is expected to strengthen Silo’s upcoming IND application. Silo remains on track for an FDA submission this year and is concurrently running a GLP-compliant toxicology study. SPC-15, developed in collaboration with Columbia University, is a 5-HT4 receptor agonist potentially eligible for the FDA’s 505(b)(2) pathway.
Via Investor Brand Network · May 14, 2025
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market
By Silo Pharma, Inc. · Via GlobeNewswire · May 14, 2025
Via Benzinga · May 1, 2025
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant
Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fibromyalgia. Conducted in minipigs, the study met all endpoints, including safety, tolerability, and pharmacokinetics, with no implant-related adverse events and sustained ketamine release for up to 22 days. CEO Eric Weisblum said the results support SP-26’s advancement as a next-generation, abuse-deterrent pain therapy. Designed for subcutaneous delivery, SP-26 avoids the dissociative effects of IV ketamine and may offer a safer alternative to opioids, potentially becoming the first at-home injectable ketamine-based therapeutic.
Via Investor Brand Network · April 30, 2025
— Successfully demonstrates strong tolerability, sustained drug release and safety
By Silo Pharma, Inc. · Via GlobeNewswire · April 30, 2025
Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia.
Via Benzinga · April 30, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
Silo Pharma (NASDAQ: SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal compound exclusively licensed from Columbia University targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease. The patent covers SPC-14’s mechanism of action focused on glutamate receptor NDMAR and serotonin 5-HT4, with preclinical studies demonstrating potential improvements in cognitive memory function. The filing supports Silo’s broader intellectual property strategy for protecting its drug platforms.
Via Investor Brand Network · April 28, 2025
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.
By Silo Pharma, Inc. · Via GlobeNewswire · April 28, 2025
Via Benzinga · March 26, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
Silo Pharma (NASDAQ: SILO) announced the first dosing in a GLP-compliant toxicology and toxicokinetics study for its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The study, part of an IND-enabling program, follows a pre-IND meeting with the FDA that aligned the company on the 505(b)(2) regulatory pathway, which may expedite approval and reduce development costs. SPC-15, a serotonin 5-HT4 receptor agonist developed in partnership with Columbia University, is intended to treat stress-related psychiatric disorders such as PTSD and anxiety.
Via Investor Brand Network · March 26, 2025
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials
By Silo Pharma, Inc. · Via GlobeNewswire · March 26, 2025
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company developing novel therapeutics and drug delivery systems, announced that the U.S. Patent and Trademark Office (USPTO) has issued an Issue Notification for its patent application (No. 17/954,864), titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent, which is set to be issued on March 4, 2025, enhances protection for Silo’s lead asset, SPC-15, an intranasal treatment for PTSD. It expands on claims from a previous patent granted in November 2022 and reinforces the company’s intellectual property strategy as it moves toward clinical trials in collaboration with Columbia University.
Via Investor Brand Network · February 27, 2025
SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025.
By Silo Pharma, Inc. · Via GlobeNewswire · February 26, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office for its lead asset, SPC-15. The patent covers a dual-action method targeting stress-induced psychiatric behaviors through a combination of a serotonin type IV receptor agonist and an N-methyl-D-aspartate receptor antagonist. CEO Eric Weisblum emphasized the filing’s role in expanding the company’s intellectual property portfolio. SPC-15, originally licensed from Columbia University, is being developed as an intranasal treatment for PTSD and anxiety, with potential eligibility for the FDA’s 505(b)(2) regulatory pathway.
Via Investor Brand Network · February 18, 2025
SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders
By Silo Pharma, Inc. · Via GlobeNewswire · February 18, 2025